CU24572B1 - Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas - Google Patents

Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas

Info

Publication number
CU24572B1
CU24572B1 CU2019000045A CU20190045A CU24572B1 CU 24572 B1 CU24572 B1 CU 24572B1 CU 2019000045 A CU2019000045 A CU 2019000045A CU 20190045 A CU20190045 A CU 20190045A CU 24572 B1 CU24572 B1 CU 24572B1
Authority
CU
Cuba
Prior art keywords
triazolones
trisubstituted
compounds
compounds derived
formula
Prior art date
Application number
CU2019000045A
Other languages
English (en)
Other versions
CU20190045A7 (es
Inventor
Dr Sven Christian
Dr Knut Eis
Steven Ferrara
Dr Stefan Gradl
Dr Judith Günther
Dr Andreas Janzer
Michael Kröber
Kery Liu
Dr Claudia Merz
Dr Thomas Mueller
Dr Duy Nguyen
Dr Michael Niehues
Dr Carl Nising
Dr Martina Schäfer
Prof Dr Sherif El Sheikh
Dr Timo Stellfeld
David Sykes
Changjia Zhao
Han Jie Zhou
Dr Katja Zimmermann
Original Assignee
Bayer Ag
Bayer Pharma AG
Harvard College
Broad Inst Inc
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG, Harvard College, Broad Inst Inc, Massachusetts Gen Hospital filed Critical Bayer Ag
Publication of CU20190045A7 publication Critical patent/CU20190045A7/es
Publication of CU24572B1 publication Critical patent/CU24572B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

<p>La presente invención proporciona compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas que son inhibidores de la dihidroorotato deshidrogenasa (DHODH) útiles para el tratamiento o prevención de trastornos hiperproliferativos e inflamatorios que poseen la fórmula general (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>en donde R1, R2, R3, R4 y R5 son como se definen en las presentes reivindicaciones, también se proveen métodos de preparación de dichos compuestos, y compuesto intermedio útiles para preparar dichos compuestos de fórmula (I).</p> <p> </p>
CU2019000045A 2016-10-27 2017-10-25 Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas CU24572B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/103643 2016-10-27
US201762569296P 2017-10-06 2017-10-06
PCT/EP2017/077252 WO2018077923A1 (en) 2016-10-27 2017-10-25 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh

Publications (2)

Publication Number Publication Date
CU20190045A7 CU20190045A7 (es) 2019-12-03
CU24572B1 true CU24572B1 (es) 2022-01-13

Family

ID=60164720

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000045A CU24572B1 (es) 2016-10-27 2017-10-25 Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas

Country Status (26)

Country Link
US (4) US10815215B2 (es)
EP (1) EP3532468B1 (es)
JP (1) JP7084389B2 (es)
KR (1) KR20190084954A (es)
CN (2) CN115557907A (es)
AU (1) AU2017351688B2 (es)
BR (1) BR112019008458A2 (es)
CA (1) CA3041643A1 (es)
CL (1) CL2019001160A1 (es)
CO (1) CO2019004137A2 (es)
CR (1) CR20190212A (es)
CU (1) CU24572B1 (es)
DO (1) DOP2019000110A (es)
EC (1) ECSP19030002A (es)
GE (1) GEP20217248B (es)
IL (1) IL266214B (es)
JO (1) JOP20190094A1 (es)
MX (1) MX2019005009A (es)
NI (1) NI201900041A (es)
PE (1) PE20191005A1 (es)
PH (1) PH12019500932A1 (es)
TN (1) TN2019000136A1 (es)
TW (1) TW201827414A (es)
UA (1) UA123688C2 (es)
UY (1) UY37461A (es)
WO (1) WO2018077923A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190094A1 (ar) * 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
JP2019535689A (ja) 2016-10-27 2019-12-12 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ４，５−縮環１，２，４−トリアゾロン
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
TW201945346A (zh) 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
EP3858361A4 (en) 2018-09-28 2021-12-01 FUJIFILM Corporation ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR ACTIVATOR USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE
TW202043208A (zh) * 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
BR112021014456A2 (pt) * 2019-02-07 2021-09-21 Janssen Biotech, Inc. Inibidores de di-hidro-orotato desidrogenase
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
EP3750892A1 (en) 2019-06-14 2020-12-16 Yerevan State University Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
US20220298107A1 (en) * 2019-08-29 2022-09-22 Janssen Biotech, Inc. Substituted urea dihydroorotate dehydrogenase inhibitors
CA3157223A1 (en) * 2019-10-10 2021-04-15 Janssen Biotech, Inc. Bi-aryl dihydroorotate dehydrogenase inhibitors
CN114222732B (zh) * 2019-10-28 2023-04-04 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用
AU2021216714A1 (en) * 2020-02-04 2022-09-29 Janssen Biotech, Inc. Heterocyclic compounds as dihydroorotate dehydrogenase inhibitors
ES2929379T3 (es) 2020-05-20 2022-11-28 Inst Nat Sante Rech Med Métodos para el tratamiento de infecciones por coronavirus
WO2021240429A1 (en) 2020-05-29 2021-12-02 Janssen Biotech, Inc. Benzofuran and benzopyran dihydroorotate dehydrogenase inhibitors
WO2021240423A1 (en) * 2020-05-29 2021-12-02 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2021240424A1 (en) 2020-05-29 2021-12-02 Janssen Biotech, Inc. Indazole and benzoisoxazole dihydroorotate dehydrogenase inhibitors
WO2021238881A1 (zh) * 2020-05-29 2021-12-02 南京明德新药研发有限公司 三氮唑酮类化合物
CA3184985A1 (en) * 2020-07-14 2022-01-20 Nanjing Zenshine Pharmaceuticals Co., Ltd. Compounds as dhodh inhibitors
CN111773214B (zh) * 2020-07-17 2021-04-20 中国人民解放军军事科学院军事医学研究院 2,4,5-三取代的1,2,4-三唑酮在制备抗病毒药物中的用途
EP3960170A1 (en) 2020-08-25 2022-03-02 Bayer AG Dosing schedule for a method of treatment with dhodh inhibitors
GB2598624A (en) * 2020-09-07 2022-03-09 Lorico Aurelio Use of triazole analogues for inhibition of a tripartite VOR protein complex in multicellular organisms
CN116249702A (zh) * 2020-09-28 2023-06-09 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物
WO2022070071A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022070069A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022167402A1 (en) 2021-02-02 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor
WO2023280181A1 (zh) * 2021-07-05 2023-01-12 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途
WO2023093812A1 (zh) * 2021-11-26 2023-06-01 南京明德新药研发有限公司 三氮唑酮类化合物的晶型及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098896A (en) 1975-09-29 1978-07-04 Chevron Research Company 1-Halohydrocarbylthio-3-hydrocarbylthio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
DE3936623A1 (de) 1989-11-03 1991-05-08 Bayer Ag Sulfonylaminocarbonyltriazolinone mit ueber schwefel gebundenen substituenten
DE3936622A1 (de) 1989-11-03 1991-05-08 Bayer Ag Halogenierte sulfonylaminocarbonyltriazolinone
DE3934081A1 (de) 1989-10-12 1991-04-18 Bayer Ag Sulfonylaminocarbonyltriazolinone
DE3709574A1 (de) 1987-03-24 1988-10-06 Bayer Ag Substituierte triazolinone
DE4110795A1 (de) 1991-04-04 1992-10-08 Bayer Ag Sulfonylaminocarbonyltriazolinone mit ueber sauerstoff gebundenen substituenten
DE3916208A1 (de) 1989-05-18 1990-11-22 Bayer Ag Substituierte triazolone
DE4342190A1 (de) 1993-12-10 1995-06-14 Bayer Ag Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen
DE4433968A1 (de) 1994-09-23 1996-03-28 Bayer Ag Verfahren zur Herstellung von Alkoxytriazolinonen
DE19627901A1 (de) 1996-07-11 1998-01-15 Bayer Ag Substituierte aromatische Carbonylverbindungen und ihre Derivate
US6444613B1 (en) 1999-03-12 2002-09-03 Hoechst Schering Agrevo Gmbh Defoliant
CA2746221A1 (en) 2008-12-08 2010-07-08 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
US20100184815A1 (en) 2008-12-19 2010-07-22 Luehr Gary W Agonists of peroxisome proliferator activated receptor-alpha
UA109150C2 (xx) 2010-09-01 2015-07-27 Аміди n-(тетразол-5-іл)- або n-(триазол-5-іл)арилкарбонової кислоти та їх застосування як гербіцидів
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN103006645A (zh) * 2011-09-27 2013-04-03 华东理工大学 2-氨基苯并噻唑衍生物作为dhodh抑制剂的应用
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US20160251341A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted triazole compounds as serine protease inhibitors
CN106543139B (zh) 2015-09-17 2020-03-17 沈阳中化农药化工研发有限公司 一种三唑酮类化合物及其用途
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)

Also Published As

Publication number Publication date
CO2019004137A2 (es) 2019-05-10
JP7084389B2 (ja) 2022-06-14
CL2019001160A1 (es) 2019-09-13
JP2019533694A (ja) 2019-11-21
UY37461A (es) 2018-05-31
CN110023302B (zh) 2022-07-26
ECSP19030002A (es) 2019-05-31
US10815215B2 (en) 2020-10-27
AU2017351688A1 (en) 2019-04-11
PE20191005A1 (es) 2019-07-15
EP3532468A1 (en) 2019-09-04
KR20190084954A (ko) 2019-07-17
CN115557907A (zh) 2023-01-03
US20220135536A1 (en) 2022-05-05
CN110023302A (zh) 2019-07-16
IL266214A (en) 2019-06-30
US20230365524A1 (en) 2023-11-16
CU20190045A7 (es) 2019-12-03
US20210188805A9 (en) 2021-06-24
WO2018077923A1 (en) 2018-05-03
CR20190212A (es) 2019-06-24
PH12019500932A1 (en) 2020-01-20
TW201827414A (zh) 2018-08-01
UA123688C2 (uk) 2021-05-12
DOP2019000110A (es) 2019-05-31
GEP20217248B (en) 2021-04-26
AU2017351688B2 (en) 2022-02-03
US11130745B2 (en) 2021-09-28
BR112019008458A2 (pt) 2019-07-09
JOP20190094A1 (ar) 2019-04-25
NI201900041A (es) 2019-06-11
US20200123129A1 (en) 2020-04-23
EP3532468B1 (en) 2022-03-23
US11713304B2 (en) 2023-08-01
US20200377472A1 (en) 2020-12-03
MX2019005009A (es) 2019-08-12
TN2019000136A1 (en) 2020-10-05
IL266214B (en) 2021-10-31
CA3041643A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
CU24572B1 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201990001A1 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EA201892147A1 (ru) Бициклические соединения
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
EA201890373A1 (ru) Пиридиновые соединения, пригодные для борьбы с фитопатогенными грибами
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
EA201891644A1 (ru) Антибактериальные соединения и их применение
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения